Entecavir treatment in kidney transplant recipients infected with hepatitis B

Clinical Transplantation

Volumn 28, Issue 9, 2014, Pages 1010-1015

  Yap, Desmond Y H ^a   Yung, Susan ^a   Tang, Colin S O ^a   Seto, Wai Kay ^a   Ma, Maggie K M ^a   Mok, Maggie M Y ^a   Kwan, Lorraine P Y ^a   Chan, Gary C W ^a   Choy, Bo Ying ^a   Yuen, Man Fung ^a   Chan, Tak Mao ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Entecavir; Hepatitis B; Kidney; Transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; VIRUS DNA; ANTIVIRUS AGENT; GUANINE; LAMIVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GENOTYPE; GRAFT RECIPIENT; HEPATITIS B; HUMAN; KIDNEY TRANSPLANTATION; MALE; MEDICAL RECORD REVIEW; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; ANALOGS AND DERIVATIVES; DRUG EFFECTS; FOLLOW UP; GENETICS; GLOMERULUS FILTRATION RATE; HEPATITIS B VIRUS; ISOLATION AND PURIFICATION; KIDNEY FUNCTION TEST; MIDDLE AGED; PROGNOSIS; RISK FACTOR;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LAMIVUDINE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANT RECIPIENTS;

EID: 84908334868     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12410     Document Type: Article

References (30)

1. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002: 36: 1246.
2. Pirson Y, Alexandre GP, Ypersele C. Long-term effect of HBS antigenemia on patient survival after renal transplantation. N Engl J Med 1977: 296: 194.
3. Parfrey PS, Forbes RD, Hutchinson TA et al. The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation 1984: 37: 461.
4. Harnett JD, Zeldis JB, Parfrey PS et al. Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation 1987: 44: 369.
5. Bang BK, Yang CW, Yoon SA et al. Prevalence and clinical course of hepatitis B and hepatitis C liver disease in ciclosporin-treated renal allograft recipients. Nephron 1995: 70: 397.
6. Parfrey PS, Forbes RD, Hutchinson TA et al. The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation 1985: 39: 610.
7. Fornairon S, Pol S, Legendre C et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996: 62: 297.
8. Chan TM, Wu PC, Li FK, Lai CL, Cheng IK, Lai KN. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998: 115: 177.
9. Durlik M, Gaciong Z, Rowinska D et al. Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transpl Int 1998: 11(Suppl 1): S135.
10. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996: 74: 512.
11. Filik L, Karakayali H, Moray G et al. Lamivudine therapy in kidney allograft recipients who are seropositive for hepatitis B surface antigen. Transplant Proc 2006: 38: 496.
12. Yap DY, Tang CS, Yung S, Choy BY, Yuen MF, Chan TM. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. Transplantation 2010: 90: 325.
13. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004: 77: 859.
14. Chan TM, Tse KC, Tang CS, Lai KN, Ho SK. Prospective study on lamivudine-resistant hepatitis B in renal allograft recipients. Am J Transplant 2004: 4: 1103.
15. Daude M, Rostaing L, Saune K et al. Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients. Transplantation 2011: 91: 916.
16. Tse KC, Yap DY, Tang CS, Yung S, Chan TM. Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B. Clin Transplant 2010: 24: 207.
17. Krummel T, Parvez-Braun L, Frantzen L et al. Tenofovir-induced acute renal failure in an HIV patient with normal renal function. Nephrol Dial Transplant 2005: 20: 473.
18. Lampertico P, Vigano M, Facchetti F et al. Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. Nephrol Dial Transplant 2011: 26: 2037.
19. Lai HW, Chang CC, Chen TH, Tsai MC, Chen TY, Lin CC. Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients. J Formos Med Assoc 2012: 111: 439.
20. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011: 106: 1264.
21. Tenney DJ, Rose RE, Baldick CJ et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009: 49: 1503.
22. Sherman M, Yurdaydin C, Simsek H et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008: 48: 99.
23. Nankivell BJ, Gruenewald SM, Allen RD, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995: 59: 1683.
24. Ho SK, Yam WC, Leung ET et al. Rapid quantification of hepatitis B virus DNA by real-time PCR using fluorescent hybridization probes. J Med Microbiol 2003: 52: 397.
25. Hu TH, Tsai MC, Chien YS et al. A novel experience of antiviral therapy for chronic hepatitis B in renal transplant recipients. Antivir Ther 2012: 17: 745.
26. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006: 354: 1011.
27. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006: 354: 1001.
28. Kamar N, Milioto O, Alric L et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008: 86: 611.
29. Fontaine H, Vallet-Pichard A, Chaix ML et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005: 80: 1086.
30. Matthews SJ. Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther 2006: 28: 184.